25th Edition of Porto Cancer Meeting 2018
Cancer Wars: The Immune Force Awakens
Department of Cellular Therapy, Oslo University Hospital-Radiumhospitalet, Oslo, Norway
Sébastien Wälchli is a senior scientist and group leader (translational research group) at the Department of Cellular Therapy at Oslo University Hospital-Radiumhospitalet. The research group in close connection with the immunomonitoring unit is involved in developing immunotherapy solutions such as TCR, CAR and improved/universal cellular systems. SW leads the molecular biology service supporting the TCR platform, which is based on the isolation of TCRs from patients responding to vaccination. He is head of the CAR platform which delivers pre-clinically validated molecules. His group is also developing effector cell for universal use. SW has an MSc in bacterial genetics from the University of Geneva and holds a PhD from a University/Industry program (U of Geneva and Ares Serono) in Molecular Biology. He then performed a postdoc in cellular biology and started his career as a researcher in Immunology 10 years ago. He co-authors more than 50 peer-reviewed articles, is co-inventor of 10 patents and has been the founder of 1 biotech company (Zelluna Immunotherapy). He is a member of different immunological and oncological societies, member of the editorial board of BMC Cancer and co-organizer of the PIVAC meeting 2018 in Oslo.